Literature DB >> 31551243

Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients.

Yoshihiro Inamoto1, Jennifer White2, Reiko Ito1, Paul J Martin2,3, Giancarlo Fatobene2, Ayumu Ito1, Takashi Tanaka1, Saiko Kurosawa1, Sung-Won Kim1, Merav Bar2,3, Mohamed L Sorror2,3, Brenda M Sandmaier2,3, Stephanie J Lee2,3, Takahiro Fukuda1, Mary E D Flowers2,3.   

Abstract

Although differences in the incidence of chronic graft-versus-host disease (GVHD) across the races have been suggested, these have not been systematically investigated. This study compared the incidence, sites, severity, and outcomes of late acute GVHD and chronic GVHD according to National Institutes of Health (NIH) consensus criteria between Japanese (n = 413) and white (n = 708) patients after first allogeneic hematopoietic cell transplantation. Analysis was stratified according to bone marrow transplantation (BMT) or peripheral blood stem cell transplantation (PBSCT). Japanese patients, compared with white patients, had a similar incidence of late acute GVHD (BMT, 19% vs 16%; PBSCT, 19% vs 16%) but experienced more frequent liver late acute GVHD as defined by transaminase elevation (BMT, 79% vs 8%; PBSCT, 92% vs 33%) and less frequent gastrointestinal late acute GVHD (BMT, 11% vs 58%; PBSCT, 20% vs 68%). Japanese patients were more likely to discontinue systemic immunosuppression after late acute GVHD than white patients (hazard ratio, 3.68; 95% confidence interval, 1.96-6.94; P < .001). Japanese patients, compared with white patients, had a lower incidence of chronic GVHD (BMT, 15% vs 30% [P = .002]; PBSCT, 37% vs 45% [P < .001]) and experienced more frequent chronic GVHD of the mouth, eyes, and liver and less frequent gastrointestinal chronic GVHD. The duration of immunosuppressive treatment of NIH chronic GVHD was similar between the races. These differences could not be entirely attributed to practice variation between the centers. This study shows that the incidence, affected sites, severity, and clinical outcomes of late acute GVHD and NIH chronic GVHD differ between Japanese and white patients.
© 2019 by The American Society of Hematology.

Entities:  

Year:  2019        PMID: 31551243      PMCID: PMC6759734          DOI: 10.1182/bloodadvances.2019000386

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  31 in total

1.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

2.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

3.  Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.

Authors: 
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

4.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers.

Authors:  W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum
Journal:  N Engl J Med       Date:  2001-01-18       Impact factor: 91.245

5.  Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.

Authors:  Hakumei Oh; Fausto R Loberiza; Mei-jie Zhang; Olle Ringdén; Hideki Akiyama; Takayoshi Asai; Shuichi Miyawaki; Shinichiro Okamoto; Mary M Horowitz; Joseph H Antin; Asad Bashey; Jennifer M Bird; Matthew H Carabasi; Joseph W Fay; Robert Peter Gale; Roger H Giller; John M Goldman; Gregory A Hale; Richard E Harris; Jean Henslee-Downey; Hans-Jochem Kolb; Mark R Litzow; Philip L McCarthy; Steven M Neudorf; Derek S Serna; Gerard Socié; Pierre Tiberghien; A John Barrett
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

6.  Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation.

Authors:  Ming-Tseh Lin; Barry Storer; Paul J Martin; Li-Hui Tseng; Ted Gooley; Pei-Jer Chen; John A Hansen
Journal:  N Engl J Med       Date:  2003-12-04       Impact factor: 91.245

Review 7.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

8.  New classification of chronic GVHD: added clarity from the consensus diagnoses.

Authors:  M Arora; S Nagaraj; J Witte; T E DeFor; M MacMillan; L J Burns; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2008-09-15       Impact factor: 5.483

9.  Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria.

Authors:  Madan Jagasia; Jennifer Giglia; Wichai Chinratanalab; Sheri Dixon; Heidi Chen; Haydar Frangoul; Brian Engelhardt; Stacey Goodman; John Greer; Adetola Kassim; David Morgan; Katherine Ruffner; Friedrich Schuening
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-24       Impact factor: 5.742

10.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research.

Authors:  Sergio Giralt; Karen Ballen; Douglas Rizzo; Andreas Bacigalupo; Mary Horowitz; Marcelo Pasquini; Brenda Sandmaier
Journal:  Biol Blood Marrow Transplant       Date:  2009-03       Impact factor: 5.742

View more
  2 in total

1.  Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Paul J Martin; Stephanie J Lee; Amin A Momin; Laura Tabellini; Lynn E Onstad; Joseph Pidala; Mary E D Flowers; Richard L Lawler; Hiroyuki Katayama; Samir Hanash; John A Hansen
Journal:  Blood Adv       Date:  2020-06-09

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.